Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.
|
29445446 |
2018 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A total of 7 publicly available and independent RCC miRNA expression profiling datasets were collected, and 2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified.
|
30344735 |
2018 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified and validated multiple miRNAs dysregulated in ccRCC tissues; miR-155-5p and miR-210-3p were predictive of ccRCC recurrence, pointing to potential utility as biomarkers and underlying biological mechanisms.
|
30201497 |
2018 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that renal cell carcinoma progression is promoted by TWIST1 suppression mediated by miR-210-3p.
|
28152509 |
2017 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with higher levels of miR-210, miR-221 and miR-1233 presented a higher risk of specific death by RCC and a lower cancer-specific survival.
|
29262564 |
2017 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of miR-210 was significantly higher in the serum of renal carcinoma than in the control group (P < 0.001).
|
26985942 |
2016 |
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a cohort of 45 patients, the high expression of miR-21 (HR: 5.46, 95%CI: 2.02-53.39) and miR-210 (HR: 6.85, 95%CI: 2.13-43.36), the low expression of miR-141 (HR: 0.16, 95%CI: 0.004-0.18), miR-200c (HR: 0.08, 95%CI: 0.01-0.43) and miR-429 (HR: 0.18, 95%CI: 0.02-0.50) were associated with poor cancer-specific survival (CSS) following RCC resection.
|
25974855 |
2015 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.
|
26426010 |
2015 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, many studies using miRNA microarray analysis demonstrated that miR-210 expression in clear cell carcinoma (CCC), which is the largest subtype of RCC, was significantly upregulated in tumor tissue.
|
24212760 |
2014 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For serum samples, the average level of miR-210 was significantly higher in cRCC patients than in controls (p<0.001).
|
23064048 |
2013 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression levels of miR-210 in RCC tumor tissue were independently validated.
|
23150176 |
2013 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Five miRNAs highly upregulated in RCC4 + VHL and five miRNAs highly downregulated in RCC4 + VHL were studied further, in addition to miR-210, which is regulated by the HIF-VHL system. miRNA expression was also measured in 31 cc RCC tumours compared to adjacent normal tissue.
|
20964835 |
2010 |